{"638747":{"#nid":"638747","#data":{"type":"news","title":"Innovations Selected for Biolocity Launch","body":[{"value":"\u003Cp\u003EThe Biolocity team is excited to announce the faculty-lead innovations selected to participate in the newest cohort of\u0026nbsp;\u003Ca href=\u0022https:\/\/biolocity.gatech.edu\/programs\/#Launch\u0022\u003EBiolocity Launch\u003C\/a\u003E! In addition to receiving funding to support commercialization milestones, awardees join a year-long collaboration with consultants and business advisors for project management and longitudinal coaching to accelerate the development of their patient-impacting technologies.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EEach year, Biolocity opens an intensive, multi-stage application process that provides applicants with the opportunity to receive pitch coaching, market assessments, and competitive analysis needed for commercial success. Faculty work with entrepreneur advisors to de-risk their technology at each application stage before final acceptance into the program by an oversight committee comprised of venture capitalists, entrepreneurs, clinicians, biomedical engineers, and university technology transfer experts.\u003C\/p\u003E\r\n\r\n\u003Cp\u003EBelow are the select projects included in this year\u0026rsquo;s cohort:\u003C\/p\u003E\r\n\r\n\u003Col\u003E\r\n\t\u003Cli\u003E\u003Cstrong\u003EDynamic Sampling Platform\u003C\/strong\u003E: This platform technology aims to provide simple, accurate, and low-cost quality monitoring for cell therapy bioreactors. Principal Investigators: Andrei Fedorov, PhD, Georgia Tech, Edwin Horwitz, MD, Emory University, and Mason Chilmonczyk, PhD, Georgia Tech.\u003C\/li\u003E\r\n\t\u003Cli\u003E\u003Cstrong\u003EFocused Cryo\u003C\/strong\u003E: A cryoablation system designed to aid in targeting peripheral nerves in a highly precise manner. The platform has applications in metabolic syndromes, obesity, hypertension, diabetes, and chronic pain. Principal Investigators: David Prologo, MD, FSIR, Emory University.\u003C\/li\u003E\r\n\t\u003Cli\u003E\u003Cstrong\u003ENanoCliq\u003C\/strong\u003E: A vaccine technology that leverages protein nanoparticle platform to prevent the onset of Leishmaniasis, a fatal disease that currently has no vaccine available. Principal Investigator: M.G. Finn, PhD, Georgia Tech.\u003C\/li\u003E\r\n\t\u003Cli\u003E\u003Cstrong\u003ENew Therapeutic for Inflammatory Bowel Disease (IBD):\u003C\/strong\u003E\u0026nbsp;The development of an LRH-1 agonist drug which increases innate steroid production specifically at the site of inflammation in the gut. Principal Investigators: Nathan Jui, PhD, Emory University, Eric Ortlund, PhD, Emory University, and John Calvert, PhD, Emory University.\u003C\/li\u003E\r\n\t\u003Cli\u003E\u003Cstrong\u003ETwice Therapeutics\u003C\/strong\u003E: A two-step method that can deliver long-lasting gene therapies to diseased tissues without re-engineering viruses. Principal Investigators: James Dahlman, PhD, Georgia Tech and Eric Sorscher, MD, Emory University\u003C\/li\u003E\r\n\u003C\/ol\u003E\r\n\r\n\u003Cp\u003E\u0026ldquo;We are fortunate in this current climate to continue to be able to provide funding that will assist the commercialization of these promising technologies,\u0026rdquo; says Manuel Kingsley, interim director of the Biolocity Program. \u0026ldquo;While research may look different this year, the passion these innovators have for improving healthcare delivery is unwavering as is our team\u0026rsquo;s commitment to their advancement. We look forward to working with each awardee to support their technology development.\u0026rdquo;\u003C\/p\u003E\r\n\r\n\u003Cp\u003EFunding and commercialization support provided by Biolocity is used to bridge the gap in development between early-stage university research and its path to the market. If you are interested in commercialization guidance for a device, therapeutic, or platform technology with the ability to positively impact human health,\u0026nbsp;\u003Ca href=\u0022https:\/\/bit.ly\/biolocity_meeting\u0022\u003Eschedule a meeting here\u003C\/a\u003E.\u003C\/p\u003E\r\n\r\n\u003Cp\u003ETo learn more about Biolocity\u0026rsquo;s funding and partnership opportunities, visit\u0026nbsp;\u003Ca href=\u0022http:\/\/www.biolocity.org\/\u0022\u003Ewww.Biolocity.org\u003C\/a\u003E.\u003C\/p\u003E\r\n","summary":null,"format":"limited_html"}],"field_subtitle":"","field_summary":"","field_summary_sentence":[{"value":"Five research innovations from Emory University and Georgia Tech selected for Biolocity Launch."}],"uid":"35486","created_gmt":"2020-09-03 14:09:37","changed_gmt":"2020-09-03 14:23:43","author":"Christina Wessels","boilerplate_text":"","field_publication":"","field_article_url":"","dateline":{"date":"2020-09-03T00:00:00-04:00","iso_date":"2020-09-03T00:00:00-04:00","tz":"America\/New_York"},"extras":[],"related_links":[{"url":"http:\/\/www.biolocity.gatech.edu","title":"Biolocity"}],"groups":[{"id":"1254","name":"Wallace H. Coulter Dept. of Biomedical Engineering"}],"categories":[{"id":"135","name":"Research"},{"id":"138","name":"Biotechnology, Health, Bioengineering, Genetics"}],"keywords":[{"id":"341","name":"innovation"},{"id":"364","name":"Funding"}],"core_research_areas":[{"id":"39441","name":"Bioengineering and Bioscience"}],"news_room_topics":[],"event_categories":[],"invited_audience":[],"affiliations":[],"classification":[],"areas_of_expertise":[],"news_and_recent_appearances":[],"phone":[],"contact":[{"value":"\u003Cp\u003E\u003Ca href=\u0022mailto:christina.wessels@bme.gatech.edu\u0022\u003EChristina Wessels\u003C\/a\u003E\u003C\/p\u003E\r\n","format":"limited_html"}],"email":["christina.wessels@bme.gatech.edu"],"slides":[],"orientation":[],"userdata":""}}}